ArticleClinical kidney journal2025
From weight loss to muscle loss: rhabdomyolysis linked to semaglutide.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyolysis is a clinical syndrome characterized by the breakdown of skeletal muscle, leading to the release of creatine kinase (CK), myoglobin and electrolytes into the circulation. This can result in acute kidney injury and other complications. Common etiologies include trauma, medications and metabolic disorders. We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6 days after increasing his weekly dose from 1.7 mg to 2.4 mg. The dose had been titrated weekly from 0.25 mg to 1.0 mg, then to 1.7 mg, and finally to 2.4 mg. Laboratory evaluation revealed markedly elevated CK (16 202 U/L; normal: 20-200 U/L) and liver enzymes (aspartate aminotransferase: 279 U/L, alanine aminotransferase: 77 U/L), consistent with rhabdomyolysis. After excluding other common causes through clinical assessment and diagnostic workup, this case underscores the importance of recognizing this rare but potentially serious adverse effect of semaglutide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.